We first examined the presence of the PLCG1-S345F mutation in a series of 101 formalin-fixed, paraffin-embedded (FFPE) PTCLs samples including 60 AITL and 41 peripheral T-cell lymphoma not otherwise specified (PTCL-NOS). Clinical data for the patients and some mutational and GEP data have been reported in two previous studies 6, 9 (see Online Supplementary Appendix for further information).
First, DNA was extracted from tumor from the FFPE samples of this group of patients. The PLCG1-S345F mutation was analyzed using two independent techniques, as previously reported 14 (Online Supplementary Appendix) . Only those cases found to be positive by both techniques were considered as mutated. All experiments were carried out blinded with respect to the clinical data.
The PLCG1-S345F mutation was found in 12.9% of the patients (13 of 101 PTCLs), comprising 11.7% (7 of 60) of AITL and 14.6% (6 of 41) of PTCL-NOS patients (Table 1) , of whom 1 of 6 showed AITL-features. Interestingly, no correlation was found between the presence of RHOA and PLCG1 mutation in this series (data not shown).
We analyzed the association of PLCG1 mutation with clinical data, and found no clear association between the PLCG1 mutation and overall survival (OS) or other prognostic factors in the whole series; however, we found that PLCG-mutated PTCL-NOSs showed a lower OS (log rank χ 2 =3.81; P=0.05) (Figure 1 ). There was also an association with response to treatment (P=0.08) that narrowly failed to reach statistical significance, probably as a consequence of the small sample (Online Supplementary Tables S1 and S2) .
Tissue micro arrays (TMA) were also constructed from FFPE samples and TMA sections were stained by the Endvision method with a heat-induced antigen-retrieval step for CD3, CD30, NFATc1, Ki67, p-ERK antibodies and NF-KB subunits for the classic and alternative NF-KB pathways, p50 and p52, respectively. Cases were considered positive for each marker following previously reported cutoff values for each. 6, 9, 14 Reactive tonsil tissue was included as a control. The primary antibodies were omitted to provide negative controls (Online Supplementary Appendix and Online Supplementary Table S3 ).
Immunohistochemical studies revealed positivity for CD3 in 87.1% (88 of 101), CD30 in 16.8% (17 of 101) and Ki67 in 21.8% (22 of 101) of the cases. Nuclear immunostaining for NFATc1, p-ERK, p50 and p52 was found in 66.3% (67 of 101), 29.7% (30 of 101), 73.3% (74 of 101) and 61.4% (62 of 101) of the cases, respectively.
No significant correlation was found between the presence of the PLCG1-S345F mutation and NFATc1 expression, although 66.7% of the mutated cases (8 of 12) were positive. This figure is lower than the 81.8% previously reported for CTCLs. Overexpression of NFAT in nonmutated cases could be explained by the presence of a preserved TCR/CD3 pathway in this subgroup of tumors. On the other hand, a direct statistically significant relationship was found between the presence of the PLCG1-S345F Figure 2 ). Analyzing this in greater depth, with respect to the histological type diagnosed, we found that the statistical relationship with CD30 was maintained in the PTCL-NOS and AITL groups (Online Supplementary Tables S1, S2 and S4). Increased signaling from mutated PLCG1, associated with increased NF-kB activity and CD30 expression, could theoretically replace the survival signaling from T-cell receptor. These data are consistent with previously published data showing that CD30 and TCR signaling are mutually exclusive in PTCL. 8, 9 These findings are of potential therapeutic relevance, since PLC and NF-kB inhibition and CD30-targeted treatments could be explored for PLCG1-mutated cases, thereby contributing to the selection of targeted treatment based on the molecular features of the tumors.
